首页> 美国卫生研究院文献>Scientific Reports >Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism
【2h】

Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism

机译:针对细胞膜受体GPBAR1的基于结构的药物设计:利用胆汁酸支架进行选择性激动

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Bile acids can regulate nutrient metabolism through the activation of the cell membrane receptor GPBAR1 and the nuclear receptor FXR. Developing an exogenous control over these receptors represents an attractive strategy for the treatment of enterohepatic and metabolic disorders. A number of dual GPBAR1/FXR agonists are known, however their therapeutic use is limited by multiple unwanted effects due to activation of the diverse downstream signals controlled by the two receptors. On the other hand, designing selective GPBAR1 and FXR agonists is challenging since the two proteins share similar structural requisites for ligand binding. Here, taking advantage of our knowledge of the two targets, we have identified through a rational drug design study a series of amine lithocholic acid derivatives as selective GPBAR1 agonists. The presence of the 3α-NH2 group on the steroidal scaffold is responsible for the selectivity over FXR unveiling unprecedented structural insights into bile acid receptors activity modulation.
机译:胆汁酸可以通过激活细胞膜受体GPBAR1和核受体FXR来调节营养物质的代谢。开发出对这些受体的外源控制代表了一种治疗肝肠和代谢疾病的有吸引力的策略。许多双GPBAR1 / FXR激动剂是已知的,但是由于两种受体控制的多种下游信号的激活,它们的治疗用途受到多种有害作用的限制。另一方面,设计选择性GPBAR1和FXR激动剂具有挑战性,因为这两种蛋白具有相似的配体结合结构要求。在这里,利用我们对这两个靶点的了解,我们通过合理的药物设计研究,确定了一系列胺类脂石酸衍生物作为GPBAR1选择性激动剂。甾体骨架上3α-NH2基团的存在决定了对FXR的选择性,从而揭示了对胆汁酸受体活性调节的前所未有的结构见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号